.

follow-on-google-news

ICICI Prudential Mutual Fund is a prominent asset management company in India, offering a diverse range of investment solutions to retail and institutional investors. With a focus on delivering consistent returns and managing risks effectively, it stands as one of the leading players in India’s mutual fund industry. 

Here are the pharma stocks in which ICICI Prudential Mutual Fund brought stakes up to 3.60%; 

Aurobindo Pharma Ltd. 

Aurobindo Pharma Limited is an Indian pharmaceutical firm. The Company primarily manufactures and markets active pharmaceutical ingredients, branded medications, generic pharmaceuticals, and associated services. 

Note: If you want to learn Candlesticks and Chart Trading from Scratch, here’s the best book available on Amazon! Get the book now!

With a market capitalization of Rs 65,027.47 crore, on Tuesday, the shares closed at Rs 1,109.80 per share, increased around 2.21 percent as compared to the previous closing price. 

ICICI Prudential Mutual Fund brought 2,11,10,103 equity shares which is equivalent to 3.60 percent of the company as of March 2024. 

Looking into the company’s financial performance, revenue increased by 14 percent from Rs 6,407 crore in Q3FY23 to Rs 7,352 crore in Q3FY24. During the same period, net profit increased by 91 percent, from Rs 491 crore to Rs 940 crore. 

Mankind Pharma Ltd. 

Mankind Pharma Limited is an Indian pharmaceutical firm. The Company develops, manufactures, and markets a wide variety of pharmaceutical formulations for acute and chronic therapeutic areas, as well as certain consumer healthcare items. 

With a market capitalization of Rs 91,935.05 crore, on Tuesday, the shares closed at Rs 2,295.00 per share, increased around 0.77 percent as compared to the previous closing price. 

ICICI Prudential Mutual Fund brought 64,17,821 equity shares which is equivalent to 1.60 percent of the company as of March 2024

Looking into the company’s financial performance, revenue increased by 21 percent from Rs 1,936 crore in Q3FY23 to Rs 2,359 crore in Q3FY24. During the same period, net profit increased by 95 percent, from Rs 249 crore to Rs 487 crore. 

Written by:- Abhishek Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.